key: cord-0035559-6419022a
authors: Charpidou, Adrianni; Harrington, Kevin J.; Syrigos, Konstantinos N.
title: Management of Malignant Pleural Effusions
date: 2006
journal: Tumors of the Chest
DOI: 10.1007/3-540-31040-1_49
sha: 58319597a23b48612b51c474a9d412ba5af9be71
doc_id: 35559
cord_uid: 6419022a

nan

Malignant pleural effusion is diagnosed when exfoliated malignant cells are found in pleural fluid or when pleural tissue is invaded by malignant cells. Malignancy is one of the most common causes of exudative pleural effusions. In postmortem examinations of patients who died of cancer, the incidence of malignant effusion was 16% [1] . Carcinoma of any organ can metastasize to the pleura. However, lung cancer is the most common cause of malignant effusions with an incidence of 40%. When first evaluated, approximately 15% of that group of patients exhibited pleural effusion and up to 50% of the patients with an advanced disease may acquire a pleural effusion during the course of their disease [2±4] . Breast cancer is the second cause with an incidence of 25%. Lymphomas account for 10% of all malignant effusions and are the most common cause of chylothorax. Other solid tumors, such as ovarian and gastric cancer, represent the 5% or less of malignant pleural effusions while in 3±10% of patients the effusion is due to malignancy of unknown origin [5] . The incidence of mesothelioma varies according to the geographic location.

The lymphatic drainage from the pleural space occurs through the stomas of the parietal pleura. The liquid travels through lymphatic channels toward the mediastinal lymph nodes. Any interference in its path can result in a pleural effusion. Nevertheless, the latter mechanism cannot solely explain the formation of all malignant effusions. Firstly, these effusions are exudates and the normal pleural fluid has low protein concentration that makes its accumulation a transudate. Secondly, the rate of fluid formation is much higher than normal. The normal rate of pleural fluid formation is 0.01 mL/kg per hour. In many patients with malignant pleural effusions it is common for the fluid egress to exceed the 100 mL/ 24 h as measured through chest tube drainage. Thirdly, malignant cells are found in more than 90% of these effusions and in addition, many of them are bloody which can be justified only by the invasion of parietal pleura from the tumor as it obstructs the lacunae of the lymphatics.

However, it has been shown that many of these patients have effusions only when their visceral pleural is involved [1, 6] . The visceral involvement represents hematogenous spread of cancer and leads to secondary metastases to the pleural space and parietal side. The presence of pleural metastases may increase the permeability of the capillaries in the visceral and/or parietal pleura. This also explains how malignant effusions are exudates. Furthermore, the existence of mediastinal lymph node involvement decreases the lymphatic drain-age and leads to an increase in fluid input in the pleural space by traversing the visceral pleura.

The above suggests that the combination of increased fluid formation and the decreased capacity of the lymphatics are the two mechanisms which can explain the genesis of malignant effusions and the reason why some patients with pleural metastases have effusions while others do not [2, 7] . Postmortem studies indicate that only 55±60% of the patients with proven pleural metastases have developed pleural effusions. Parietal pleural involvement in lung cancer results from either neoplastic spread across the pleural cavity from visceral pleura or by the attachment of exfoliated cells from the visceral pleura. The visceral pleura impairment is due to pulmonary arterial invasion and embolization.

Adenocarcinoma of the lung is the most common histological type associated with malignant pleural infusion; it spreads by contiguity due to its peripheral location and has the propensity to invade the vessels [2] . Some patients with malignancy have cytology-negative pleural effusions and no direct pleural involvement from the tumor. The term ªparamalignant effusionsº refers to those effusions that are not a direct result of the pleura invasion from the tumor but are still related to the primary malignancy [2, 3] . Not all ªparamalignant effusionsº exclude operability in lung cancer. Important examples are the parapneumonic effusions due to postobstructive pneumonia and the transudate effusions secondary to postobstructive atelectasis. Other local effects (Table 49 .1) of the tumor causing ªparamalignant effusionsº are: (1) lymphatic obstruction, as mentioned before, (2) obstruction of the thoracic duct with the development of chylothorax, and (3) the trapped lung caused by extensive tumor involvement of visceral pleura. Systemic effects of the tumor can result in effusions with pulmonary embolism, hypoalbuminemia, and cachexia. In addition, adverse events of the therapy can also result in effusions. This category includes radiation therapy and antineoplastic drugs such as bleomycin, methotrexate, cyclophosphamide, and taxanes.

Dyspnea on exertion and cough are the most common symptoms that patients refer to on admission. The presence and degree of dyspnea depend on the volume of the effusion and the underlying pulmonary function. The mechanism of dyspnea is under scientific research. Decrease of the compliance of the chest wall, contralateral shift of the mediastinum, depression of the ipsilateral diaphragm, decrease in ipsilateral lung volume, and neurogenic reflexes from lung and chest wall may be considered as probable mechanisms. Obstructive pneumonitis, atelectasis, and malignant infiltration of the pulmonary parenchyma may provoke additional causes of dyspnea. Chest pain indicates involvement of parietal pleura and is most common in mesothelioma. It is described as dull and aching rather than sharp and pleuritic. Pleural metastases indicate advanced disease where patients can present with weight loss, anorexia, and malaise. Physical examination can easily detect the presence of fluid of the malignant effusion which commonly exceeds 500 mL.

Chest radiography shows moderate to large fluid accumulation (500±2,000 mL) in approximately 75% of patients with malignant effusion with 10% having effusions with less than 500 mL and 10% having massive pleural effusions. The term ªmassiveº refers to the occupation of the whole hemithorax with fluid.

Bilateral effusions are common when the primary site of cancer has spread not locally to the lungs but hematogenously. More than 50% of the cases of bilateral effusions with a normal heart size are diagnosed as malignant or paramalignant. Lupus and rheumatoid pleuritis, benign asbestos pleural effusion, hypoalbuminemia, and constrictive pericarditis should also be considered in the differential diagnosis of bilateral effusions.

Usually large effusions push the mediastinum to the contralateral site. Differential diagnosis of mediastinal effusions are: (1) mainstem bronchial obstruction by tumor and atelectasis, (2) trapped lung, (3) fixed mediastinum caused by malignant lymphadenopathy, and (4) extensive infiltration of the ipsilateral lung by tumor radiographically mimicking a large effusion.

Computerized tomography (CT) can provide useful information of lymph node involvement, underlying parenchymal diseases, or co-existing metastases [8, 9] . The role of magnetic resonance imaging (MRI) seems to be limited to malignant pleural effusions but it is considered a useful technique in the assessment of mediastinal and chest wall invasion by virtue of its ability to determine fat-stripe invasion and involvement of the diaphragm [9, 10] . The role of the novel and promising technique of fluorodeoxyglucose positron emission tomography (FDG-PET) is still being evaluated for malignant effusions. Recent studies which compare the efficacy of FDG-PET to CT in differentiating benign pleural effusion from malignant and/or pleural involvement in patients with lung cancer, showed that the new diagnostic method is a highly accurate and reliable non-invasive technique [11, 12] .

Diagnostic thoracentesis must be performed in any patient where a pleural effusion of more than 1 cm thick is detected in the lateral decubitus position. Almost all malignant pleural effusions are exudates with a protein concentration of about 4 g/dL. In some cases, such as the pleural fluid accumulation secondary to atelectasis or to lymph node involvement, they can be transudates. The differential cell count is useful to determine the etiology of the fluid. The malignant effusions are characteristically lymphocytic with a range of 50±75% but certainly less than that which can be seen in tuberculous pleurisy (> 90%). The reason for this lymphocytosis is unclear. The lymphocytes are predominantly Ttype and appear to play a key role in local defense against tumor invasion. Pleural fluid eosinophilia (eosinophils > 10%) usually signifies a benign self-limited disease but it cannot exclude malignancy. The frequency of eosinophilia in malignant effusions varies from 10% to 40%. In some populations, eosinophilic effusions are as likely to be malignant as non-eosinophilic ones [2, 13, 14] . Polymorphonuclear leukocytes usually represent less than 25% of the cell population. Although malignancy is the most common cause of bloody effusions, at least half of them are not grossly hemorrhagic (RBC count < ;10,000 cells/mL). A bloody malignant pleural effusion can result from either direct invasion of blood vessels, increased capillary permeability caused by vasoactive substances produced from tumor cells, occlusion of venules, or tumor-induced angiogenesis [2] . Although the pleural fluid lactate dehydrogenase (LDH) level is used to distinguish transudative from exudative pleural effusions, it is not useful in the differential diagnosis of malignancy [15] . At the time of the diagnosis, approximately one third of malignant effusions are acidotic with a pH value less than 7. This low pH is associated with low glucose concentrations (< 60 mg/dL). The possible mechanism involves the spreading of the tumor within the pleural space. The abnormal thickening of the pleura prevents the glucose transport from blood to pleural fluid. The glucose that does enter the pleura is metabolized by normal and malignant cells to CO 2 and lactate. Additionally, the abnormal pleural barrier impairs the efflux of these end products of glucose metabolism from the pleural space, resulting in the fluid acidosis. Malignant effusions with low pH and glucose concentration are considered to have a higher initial diagnostic yield on cytological examination and a worse survival and response to pleurodesis than those with normal values. Pleural fluid pH correlates with survival [3, 16] . The amylase salivary isoenzyme of the fluid is elevated in 10±14% of malignant effusions. In the absence of esophageal rupture, elevated values of fluid amylase establish the diagnosis of malignancy, especially lung adenocarcinoma.

The diagnosis of malignant pleural effusion can be obtained by the demonstration of malignant cells in pleural fluid or in pleural tissue. Cytological examination of pleural fluid is a fast, efficient, non-invasive, and more sensitive technique than the closed pleural biopsy. The percentage of malignant effusions which is diagnosed with cytology varies from 40% to 87% [3, 15] . The frequency of positive cytological results, if the effusion is not ªparamalignantº, depends on the tumor type. Squamous cell carcinoma, Hodgkin's disease, and sarcomas are less commonly positive. Obviously the frequency also depends on the skills of the cytologist. Overall, if three separate pleural fluid specimens are submitted to an experienced cytologist, the positive diagnosis is about 70±80%. Some clinicians suggest that when the first suspicion is malignancy, several hundred milliliters of fluid should be removed at the initial diagnostic thoracentesis. This procedure, in the case of a negative initial cytological examination, involves the sucking of fluid with fewer degenerative mesothelial cells as well as freshly exfoliated malignant cells in a repeated thoracentesis [2] . In the decade since 1995, the use of other procedures, such as flow cytometry with DNA analysis and immunohistochemical staining with monoclonal antibodies to tumor markers, have been proposed in order to increase the diagnostic accuracy of cytology. Because of their low sensitivity and specificity of these techniques, they can only be used to assist in the diagnosis and not confirm it. Identification of DNA aneuploidy by flow cytometry may add to routine cytology by detecting false-negatives in the initial screening and warrant additional samples for further review. Flow cytometry with immunocytometry can identify the cell lineage (T or B cells) and the clonality of the population of lymphocytes. Therefore, it is useful when lymphoma is suspected. Immunohistochemical staining for tumor markers such as carcinoembryonic antigen (CEA), Leu-M1, mucine, and B72.3 can be used in the differential diagnosis between adenocarcinoma and mesothelioma. If the specimen is positive for at least two of these antibodies, this is a likely indication for adenocarcinoma.

On the contrary, if it is not stained for any of the antibodies and/or it is positively stained for vimentin, the diagnosis is probably mesothelioma [3, 15, 17, 18] . A tumor marker panel, such as CEA, carbohydrate antigen 15-3 (CA 15-3), cytokeratin 19 fragments (CYFRA 21-1), and cancer antigen 125 can reveal the patient that could benefit from a more aggressive and invasive diagnostic procedures when the initial cytological examination is negative [19] . Telomerase activity in recent studies has proven to be a highly diagnostic biomarker for malignancy. Additionally, when it is used as an adjunct to cytology, it significantly increases the diagnostic sensitivity [20] .

In malignant effusions, closed pleural biopsies are less sensitive than fluid cytology, with a diagnostic yield of 40±44% [3, 21] . The low sensitivity of this blind biopsy of the parietal pleura is mostly due to the distribution of tumor in unexamined areas and early stage of disease with minimal pleural involvement. Many physicians suggest that if malignancy is suspected and the cytology of thoracentesis is negative, thoracoscopy is then preferred over closed needle pleural biopsy reaching a diagnosis in more than 90% of cases. Medical thoracoscopy compared to surgical thoracoscopy, also known as ªvideo-assisted thoracic surgeryº or ªVATS,º can be performed under local anesthesia or conscious sedation and it is considerably less invasive and less expensive than VATS [22] . Medical thoracoscopy is primarily a diagnostic procedure but it can also be used for staging and in the treatment of malignant effusions. By thoracoscopy, we can achieve direct visualization of the pleural cavity and can obtain biopsies of the chest wall, the parietal or visceral pleura, the lung, the mediastinum, and the diaphragm. Thoracoscopy can also result in the complete evacuation of the pleural fluid, elimination of adhesions hindering lung expandability, and pleurodesis by talc poudrage. The diagnostic sensitivity of medical thoracoscopy is higher than that of both cytology and closed pleural biopsy (96% versus 74%, p < 0.001). The combination of all of these methods can result in a 97% diagnosis of malignant pleural effusions. The sensitivity of cytology compared to that of thoracoscopy did not vary among lung carcinomas (67% versus 96%), extrathoracic primary tumors (62% versus 96%), and diffuse malignant mesothelioma (58% versus 92%) [23] . The false-negative thoracoscopic results can be due to a physician's inexperience along with the presence of adhesions that prevent access to the neoplastic tissue. Adhesions can result from multiple attempts of therapeutic thoracentesis. Despite the great usefulness of the procedure, thoracic surgery backup should be available. VATS requires general anesthesia and single-lung ventilation. It usually combines diagnosis and treatment but it is a more extensive procedure than the medical one because several ports have to be used. VATS is not indicated when the patient cannot tolerate single-lung ventilation or if the pleural ad-hesions prevent the safe insertion of the thoracoscope. In those cases and if diagnosis remains elusive despite a successful exploratory thoracoscopy, thoracotomy is indicated when the patient has a good performance status.

Bronchoscopy has a low diagnostic yield in undiagnosed pleural effusions and it must be performed only if endobronchial lesions are suspected as a result of atelectasis or when the lung fails to expand after therapeutic thoracentesis.

Many attempts have been made to find prognostic factors in patients with recurrent malignant effusions in order to select the optimum therapeutic strategy. Clinical data and pleural fluid parameters are investigated. Pleural fluid pH and glucose concentration seems to have the best correlation with overall survival [23±25]. Uncertainty remains for the thresholds of their values. A meta-analysis of 400 patients indicated that patients with pH values less than 7.28 had a 3-month survival rate of 38.9% compared to 61.6% for patients with values over this cutoff point. Although pH is a significant predictor of the duration of survival, accuracy is low and only 54.4% of the patients predicted by pH to die within 3 months were classified correctly. Decreasing the cutoff points of pH did not increase accuracy. This study also showed that the primary origin of malignancy influences survival. Patients with neoplasms of the lung, soft tissues, kidney, ovary, gastrointestinal tract, and oropharynx had a worse median survival. It is confirmed that pH correlates with the duration of survival but it cannot be clinically used for the selection of patients who should not undergo pleurodesis based on an estimated survival [26] . In the majority of studies, as well as in the meta-analysis, clinical data such as weight loss and Karnofsky performance status scores (KPS) were not taken into consideration. Performance status measured with Karnofsky's scale has a strong correlation with the survival of patients with lung cancer, other solid tumors, and lymphomas. In recurrent malignant effusions, performance status seems to be a significant predictor of survival. Patients with KPS of more than 70 have a median survival of 395 days, compared with only 34 days for those with KPS less than 30 [27] .

The accumulation of pleural fluid in patients with cancer usually signals advanced disease and is associated with a dismal long-term survival rate. Selection of optimal treatment for each individual patient requires a careful assessment of the benefits and the risks of the treatment. Primary treatment targets should involve palliation or elimination of dyspnea, improvement of a patient's overall quality of life in order to restore daily activities, and implementation of oncological therapies. The complexity of confronting malignant effusions is reflected in the official statement of the American Thoracic Society and the European Respiratory Society as it was published in 2000 and 2001, respectively, in their guidelines [3] . The proposed therapeutic options for malignant pleural effusions include repeated thoracentesis, tube thoracostomy or thoracoscopy for the evacuation and pleurodesis, pleuroperitoneal shunts, pleural abrasion, and pleurectomy.

Therapeutic thoracentesis must be performed in all symptomatic patients with malignant pleural effusions. This alleviates dyspnea and slows the rate of recurrence. Inability to improve symptoms following therapeutic thoracentesis indicates pathology of the underlying pleura or lung such as trapped lung, atelectasis, lymphangitic carcinomatosis, or tumor embolism. Rapid recurrence of fluid imposes immediate treatment.

Repeated therapeutic thoracentesis, on an outpatient basis, is an acceptable procedure for those with poor performance status, short survival expectancy, and low pH of the pleural fluid. This reduces hospitalization and avoids the more invasive techniques. Periodic thoracentesis in moderate effusions with a combination of systemic chemotherapy can be applied in asymptomatic patients.

The volume of fluid that can be safely removed is unknown. In large effusions with a contralateral mediastinal shift, several liters of drainage are probably safe. In general, when the pleural space pressure is not measured, it is preferred to remove 1±1.5 L as long as the patient does not experience any dyspnea, cough, or chest pain [3] . The main adverse effect in rapidly removing fluid (and air) from the pleural cavity is the on-site re-expanding pulmonary edema. The mechanism of edema progression is not fully clarified, but it is believed that it is mostly related to mechanical forces causing vascular stretching or injury, and increasing capillary permeability rather than the absolute level of negative pleural pressure [28] .

The success of pleural fluid drainage can be discriminated on the basis of the relief of dyspnea and by chest X-ray. Determination of pulmonary functions and PaO 2 may be misleading. Pleural effusion tends to increase the volume of the hemithorax rather than decrease the lung volume. Therefore, the improvement of total lung capacity (TLC) after thoracentesis is only one third of the volume of the removed fluid [29] . The effect on PaO 2 varies and it can be increased, remain the same, or temporarily decreased.

Pleurodesis is the most suitable palliative treatment in patients with recurrent symptomatic malignant effusions and good performance status. The aim of the procedure is to achieve adhesion of the parietal and visceral pleura by the development of a dense fibrosis in order to prevent accumulation of fluid in the pleural cavity. Lung re-expansion is necessary for a successful pleurodesis. Pleural fluid pH (7.20) , glucose levels (60 mg/dL), and pleural space elastance (19 cm H 2 O) are used to predict the pleurodesis outcome and/or the absence of trapped lung. The measurement of elastance, defined as the decline in pleural fluid pressure in cm H 2 O after the removal of 500 mL of effusion, seems to have a better trend in accuracy than the fluid pH but not significantly. Some suggest that pH levels have more of a discriminative power to predict the outcome of pleurodesis than the trapped lung itself [30, 31] .

Pleurodesis is usually performed by installation of a chemical agent through the standard drainage chest tube or small-bore catheter (8-16F). Ideally, the chest tube must be directed posteriorly toward the diaphragm. Confirmation of lung re-expansion with X-ray shortly precedes pleurodesis [3] . A number of antineoplastic and non-antineoplastic agents are used for pleurodesis (Table 49.2). Sterilized asbestos-free talc (3 MgO, 4 SiO 2 , and H 2 O) consistently produces the highest success rates (> 90%) regardless of how it is implemented. It can be insufflated into the pleural space via medical or surgical thoracoscopy or administered in the form of slurry through a chest tube followed by tetracyclines (minocycline and doxycycline) and bleomycin. Minocycline and doxycycline have overall success rates of 73% but the unfortunate requirement of repeated doses and heavy local analgesia is thought to be the main drawback. Corynebacterium parvum has limited success while quinacrine can provoke serious toxicity in the central nervous system [2, 3, 32] . Bleomycin is an effective sclerosing agent with similar success rates to tetracycline. With bleomycin, however, there is less chest pain and fever. Generally, talc slurry appears to be more preferred due to its cost. The criticism over the use of bleomycin is that it is relatively more expensive compared with other agents. However, studies of its remarkable success rates have made bleomycin through small-bore chest tubes a more attractive, less invasive option as it reduces hospitalization time [2, 3, 30±33] . Additionally, the use of a standard dose of 60 mg bleomycin mixed with 50±100 cm 3 of sterile saline can be replaced effectively with a lower dose of 30 mg when careful selection is made of patients with no evidence of trapped lung [30] .

As mentioned above, talc pleurodesis is the most successful therapeutic palliation strategy for malignant effusions. After the pleural cavity has been drained, no more than 5 g talc must be instilled into pleural space as slurry or poudrage. The tube should be closed for 1± 2 h after instillation. With slurry, the patient must be repositioned. Slow progressive suction can be applied if trapped lung is suspected. The chest tube can be safely removed when drainage is less than 150 mL/day, usually within 48 h. If after 48 h and up until 72 h the chest tube drainage is still large (> 250 mL/day), re-instillation of the same dose of talc can be performed [3] . Talc is an inexpensive and highly effective agent. The most common complications seen in talc administration are pain and fever. Pain is ranged from non-existing to severe and can be easily controlled by the administration of local anesthesia and parenteral analgesia before the procedure. Fever is mild, probably related to the inflammatory process, and characteristically occurs 4±12 h after instillation. More serious complications, such as acute respiratory distress syndrome (ARDS), acute pneumonitis, and respiratory failure have been reported. They are mostly related to dose and particle size [3, 34, 35] . Long-term complications, such as an increasing incidence of lung cancer, have not been documented with asbestos-free products [3] .

The exact mechanism of pleurodesis has not yet clearly defined. For years, scientists believed that inflammatory cells were responsible for the fibrosis but this hypothesis can not explain the rapidness of the fibrotic procedure. The basic fibroblast growth factor (bFGF) appears to be the cornerstone of the fibrotic cascade. bFGF is a strong mitogen for fibroblasts and, as seen in in vitro studies, pleural mesothelial cells release high levels of biologically active bFGF after talc stimulation. Additionally, it has been proven that normal mesothelial cells synthesize higher amounts of bFGF than malignant ones, indicating that the presence of normal mesothelium is important for the rapid release of bFGF and, also, for a successful pleurodesis. This can support the use of talc pleurodesis by clinicians at an early stage, rather than a later one, and even for asymptomatic patients, it can be implemented before the pleura is diffusely covered with malignant deposits [32, 36] .

Failure of pleurodesis may be due to either inappropriate patient selection or with its technique. An additional option for these patients is the pleuroperitoneal shunt. This palliation treatment is suitable for patients with trapped lung or malignant chylothorax since chyle is recirculated [3] . Few complications have been associated with shunt placement. The most common is shunt occlusion (12%) and in this case, a replacement is mandatory. The possibility of seeding the peritoneum with malignant cells through the shunt is present, but not clearly documented. For these patients, there is no established alternative treatment [3] . For patients with good performance status, an expected survival of more than 6 months, trapped lung, or pleurodesis failure, pleural abrasion with or without pleurectomy can be a solution. By obliterating the pleural space, pleurodesis can be successful. However, pleurectomy is a major surgical procedure with perioperative mortality of 12% and, thus, the careful selection of patients is important [3] .

Lastly, in patients with a short survival expectancy, poor performance status, and symptomatic malignant pleural effusion, implementation of a chronic indwelling catheter can provide an effective, alternative solution.

For patients with chemosensitive tumors, such as small cell lung cancer, lymphomas, and breast cancer, systemic therapy can prove to be equally or more effective than local therapy for relieving malignant effusions. After the initial therapeutic thoracentesis, chemotherapy must be administered and pleurodesis can be delayed until systemic treatment becomes ineffective. However, if a rapid reaccumulation of fluid is present or there is a contraindication to chemotherapy, pleurodesis can be initiated [3] . Malignant effusions due to tumors of the prostate, ovary, or thyroid, or those which have arisen from germ cells, may also respond to chemotherapy.

The use of localized intrapleural chemotherapy appears as an attractive therapeutic option to maximize antineoplastic activity and minimize systemic absorption and adverse effects of chemotherapy. Doxorubicin hydro- 

Although malignant effusion can be due to the invasion of the pleura from malignant cells of any organ, lung cancer is the most common cause. Approximately 15% of these patients are diagnosed with malignant effusion on their first admittance, and 50% of them who have locally advanced or metastatic disease will develop effusion in the course of their sickness. All histological types can metastasize in the pleura but the most frequent is adenocarcinoma, probably because of its peripheral location. For patients with malignant effusion from non-small cell lung cancer, chemotherapy is not the first treatment strategy. Palliative local therapy includes careful drainage of the pleural cavity. If the patient is a candidate for pleurodesis, intrapleural application of a sclerotic agent (talc slurry or poudrage, bleomycin, or doxycycline) is performed. A large phase III study demonstrated that talc insufflation through thoracoscopy has higher success rates (82%) than the use of slurry through thoracostomy in the subgroup of patients with primary lung cancer [44] .

In patients with a good performance status (KPS > 70), complementary systemic chemotherapy must be administered. For patients with paramalignant effusions due to postobstructive atelectasis, bronchoscopy is necessary for resolution of obstruction. The prognosis of this group of patients is similar to those at the same stage without effusion [2±4].

Pleural effusion due to small cell lung cancer traditionally stages the disease as extensive. However, if the effusion is the only evidence of metastatic spread, the survival is comparable to those with a limited disease. After the initial thoracentesis, chemotherapy is considered as the first choice of treatment and pleurodesis can be delayed until recurrence [3, 45] .

Breast cancer is the most common tumor in females and it is the second cause of malignant effusions (25%), following lung cancer [46] . It has been accepted that 46% of patients with disseminating breast cancer will develop pleural metastases. The median time from the initial diagnosis until the development of pleural effusion is 41.5 months with a range of 0 to 246 months [3] . In a retrospective study of 3,856 women with a history of invasive breast carcinoma, Pokieser et al. analyzed the correlation between the site of the primary tumor and the probability to develop a malignant effusion. When the primary tumor was located in the inner quadrants, the probability of malignant pleural or pericardial effusion was 4 times higher [47] . The clinical usefulness of this observation is that a more aggressive adjuvant therapy can be administered to a particular subset of patients with breast cancer. The survival after the onset of effusion is better for breast cancer patients compared to lung cancer ones. It is related to the presence of metastatic sites of the disease in other organs. The median survival is 48 months if pleural effusion is the only evidence of recurrence and 12 months when disseminating disease is present. The diagnosis of malignant effusion due to breast cancer is relatively uncomplicated (by cytological examination of pleural fluid) and more invasive procedures are rarely demanded [48] . The expression of estrogen and progesterone receptors in primary breast tumors is undoubtedly related to the prognosis. The expression of these receptors from metastatic pleural tissue can interfere with the survival of the patient but this hypothesis remains to be confirmed since there is a lack of data [49] . Other prognostic factors such as chromosomal changes, as detected by fluorescence in situ hybridization (FISH), are under investigation but a greater number of prospective studies need to be conducted [50] . The mechanisms of pleural metastases are either through lymphatic spread, which results in an ipsilateral effusion, or through hematogenous spread, which is usually accompanied by hepatic metastases and is associated with bilateral or contralateral effusion. A less common mechanism is the direct invasion through the chest wall. Ipsilateral localization is detected in 50% of patients while contralateral localization is in 40%. Bilateral is seen in 10% of these patients [3, 51] . Systemic chemotherapy and hormone therapy are the recommended first-line therapies for recurrent breast cancer and malignant effusion. If chemotherapy is ineffective or contraindicated, local therapy must be considered. Talc pleurodesis remains the best choice with a tendency to talc insufflation through thoracostomy rather than talc slurry [44] . Distinguishing between pleural effusions due to metastases and those due to post-radiation therapy is important. The latter can occur after adjuvant radiotherapy in patients with breast tumor after segmentectomy. Post-radiation effusions are usually presented within 6 months after radiation and are resolved spontaneously.

Lymphomas rank third in frequency (10%) in cancers causing malignant effusions. Effusions occur more often in non-Hodgkin's than in Hodgkin's lymphomas. Fluid characteristics are mostly in accordance with exudate criteria than transudate criteria. Non-Hodgkin's lymphoma is the most common cause of chylothorax [5, 52] . The mechanism of fluid accumulation is blockage of the lymphatic drainage either from mediastinal nodal invasion (Hodgkin's disease) or direct infiltration of the pleura (non-Hodgkin disease). Although the diagnostic usefulness of fluid cytological examinations varies from 30% to 55% (the lowest sensitivity seen in Hodgkin's disease), chromosomal analysis has a higher sensitivity of up to 85%. The application of flow cytometry by using immunocytometry can identify cell lineage (T or B cells) as well as the clonality of the population of lymphocytes [15] . The average overall survival time is usually short and positive fluid cytology is associated with a poor prognosis. Systemic chemotherapy is the recommended treatment for malignant effusions due to lymphomas. Palliative local treatments with sclerosing agents can be provided to achieve relief of symptoms. Mediastinal radiation can help in the resolution of symptomatic pleural effusion when mediastinal node enlargement is the cause of impaired lymphatic drainage. Pleuroperitoneal shunt is a fair approach for patients with chylothorax and chemotherapy failure as chyle is recirculated [3, 53] .

Malignant pleural effusion secondary to multiple myeloma is uncommon and occurs in only 6% of patients. The diagnosis can be obtained from the measurement of fluid protein concentration, characteristically from up to 7 g/dL [54] . Electrophoresis and immunoelectrophoresis of the fluid are equally diagnostic. Pleural invasion usually originates from an adjacent lesion (ribs, sternum, and vertebra) or from chest wall plasmatocytoma. Systemic therapy is also recommended.

Malignant pleural mesothelioma (MPM) has an incidence which varies according to the geographic location. The disease is related to asbestos exposure with predominance in the population of males between 50 and 70 years of age. A long latency period is observed between time of exposure and the development of the disease with a mean time of 40 years (range of 14±72 years). Three histological types of MPM are identified: epithelial, mixed, and sarcomatous. Sarcomatous and mixed types are associated with poor prognosis as well as poor performance status, chest pain, and weight loss. They have a platelet count greater than 400,000/ L, a serum lactate dehydrogenase of more than 500 IU/lL, low hemoglobin levels, high white blood cell count, and are usually greater than 75 years of age [55, 56] . The most recent retrospective studies imply that the simian virus 40 (SV40) correlates with the development of MPM that has a poor prognosis [57] . The importance of molecular biology in cancer research must demonstrate some revolutionary deductions. The analysis of pretherapeutic gene expression in mesothelioma biopsies can predict the clinical outcome of the patient, independently of the histological type [58] , and the resistance to treatment [59] . Today, with the use of histochemical and immunohistochemical staining techniques, along with electron microscopic analysis, it is possible to obtain a diagnosis of MPM from pleural effusion in 84% of cases, starkly contrasting the once low diagnostic accuracy of only 33% derived from the cytological examination of pleural fluid associated with mesothelioma. Thoracoscopy (medical or surgical) remains the gold standard for diagnosis and staging. In reviewing the literature, there is no clearly identifiable therapeutic strategy for resectable pleural mesothelioma. Patients who are candidates for surgery are those who theoretically can achieve a complete resection of tumor (stage I±III). The percentage of 2-and 5-year survival time for stage I is 65% and 30%, respectively [60] but a long-term survival for all ªresectableº stages is disappointing with a median survival ranging from 9 to 17.3 months [56] . The strategy of a multimodal treatment approach, despite the lack of large phase III trials, appears to be a justifiable choice. Large, but not randomized, reports indicate an improved median survival (13±17 months) for patients with multimodal treatment (surgery, chemotherapy, and/or radiotherapy) compared to the best supportive care (median survival of 7 months) [60, 61] . It is of great importance to notice that these trials were conducted before the arrival of the new antifolates (pemetrexed and raltitrexed) which have changed the course of chemotherapy in MPM. Based on good results of induction/neoadjuvant chemotherapy in non-small cell lung cancer, Weder et al. [62] conducted a neoadjuvant trial for patients with potential operable MPM. They used an acceptable doubled combination of cisplatin and gemcitabine (response rates of 16±48% [63] ) for 3 cycles followed by surgery and radiotherapy. Their promising results of median survival of 23 months need further confirmation by larger randomized trials.

The role of radiotherapy as a single-modality therapy is limited. It is most commonly used as a palliative treatment of chest pain and/or as a preventive procedure of scar recurrence when thoracentesis, biopsy, or operation has been obtained. The frequency of malignant seeding after chest wall injury has been reported to have occurred in 20±50% of patients who underwent invasive techniques. Small doses of external beam radiation (21 Gy) to the chest wall, delivered 10±15 days after the invasive procedure, acts as a preventing agent.

Patients who have reached an unresectable stage of the disease are candidates for chemotherapy. Many chemotherapeutic agents have been tested as single agents in MPM with disappointing results. Only vinorelbine given on a weekly schedule has showed any acceptable results with improvement of general physical symptoms and a median survival of 10.6 months [64] . In 2003, the results from a large phase III trial by Vogelzang et al. [65] have changed the role of chemotherapy in MPM. The investigators concluded that the use of a cisplatin plus pemetrexed regimen, compared to a single regimen of cisplatin, improves median survival, pulmonary function tests, and any disease-related symptoms. Another phase III study conducted by the European Organization for Research and Treatment of Cancer (EORTC) that also used a double regimen of a new antifolate raltitrexed and cisplatin, resulted in equally encouraging data with median survival of approximately 12 months. The novel antifolate pemetrexed is a multitargeted inhibitor of dihydrofolate reductase, thymidylate synthase, and glycinamide ribonucleotide formyltransferase. The main toxicities of the double regimen are hematological, with neutropenia grade 3±4 (28%) and leukocytopenia (18%) being the predominant ones. The data of this phase III international study provided level 1 evidence for the treatment of mesothelioma patients with a combination of pemetrexed and cisplatin.

The use of intrapleural cytokine therapy has been investigated in MPM and encouraging results have been reported from small phase II studies. Interleukin-2 has shown the best activity and toxicity profile and a median survival of 18 months [66] . This promising approach remains to be confirmed by larger clinical studies.

Despite assiduous investigation, in about 3±10% of patients with malignant effusions the primary malignancy is not obvious. Delay of treatment and symptom relief is not justified because the presence of effusion indi-cates that the tumor is already disseminated. However, it is important to identify tumors that may be sensitive to hormone or chemotherapy, such as breast or ovarian cancer in women or gut and germ cell tumors in both sexes. Imaging examinations such as mammography, abdominal and pelvic ultrasonography, computerized tomography, rectal examination, and use of tumor markers (cancer antigen 125, carcinoembryonic antigen, human chorionic gonadotrophin, and a-fetoprotein) can prove useful in order to localize the primary cause of the effusion.

Malignancy of the pleural space is an area of continuous clinical and biological research. The need for better understanding of the cellular mechanisms of fluid accumulation as well as a better understanding of the administration of more effective and less toxic intrapleural therapy is imperative. The novel technology of gene therapy can be the answer to many malignancies and to malignant effusions, if problems such as therapeutic gene transfer are resolved in the years to come [67, 68] . l Malignancy is one of the most common causes of exudative pleural effusions, since in postmortem examinations of patients who died of cancer, the incidence of malignant effusion was 16%. l Lung cancer is the most common cause of malignant effusions with an incidence of 40%. When first evaluated, approximately 15% of lung cancer patients exhibit pleural effusion and up to 50% of the patients with an advanced disease may acquire a pleural effusion during the course of their disease. l Adenocarcinoma of the lung is the most common histological type associated with malignant pleural infusion; it spreads by contiguity due to its peripheral location and has the propensity to invade the vessels. l The term ªparamalignant effusionsº refers to those effusions that are not a direct result of the pleura invasion from the tumor but are still related to the primary malignancy. Not all ªparamalignant effusionsº exclude operability in lung cancer. Important examples are the parapneumonic effusions due to postobstructive pneumonia and the transudate effusions secondary to postobstructive atelectasis. l The accumulation of pleural fluid in patients with cancer usually signals advanced disease and is associated with a dismal long-term survival rate.

Pleural metastatic tumors and effusions. Frequency and pathogenic mechanisms in postmortem series

Malignancy metastatic to the pleura

Management of malignant pleural effusions

Pleural Diseases, 4th edn. Philadelphia: Lippincott

Malignant and pericardial effusions

Points to consider when choosing a biopsy method in cases of pleurisy of unknown origin

Malignant pleural effusion: would the real cause please stand up?

Pleural changes in malignant pleural effusions: appearance on computed tomography

Diagnostic imaging of lung cancer

Magnetic resonance (MR) imaging of the chest: state of the art

Clinical role of F-18 fluodeoxyglucose positron emission tomography imaging in patients with lung cancer and suspected malignant pleural effusion

Evaluation of pleural disease with F-18 fluodeoxyglucose positron emission tomography imaging

Probability of malignancy in pleural eosinophilia

Etiology and prognostic significance of eosinophilic pleural effusion

Diagnostic principles in pleural diseases

Multilevel and continuous pleural fluid pH ratios for evaluating malignant pleural effusions

Immunohistochemical evaluation of seven monoclonal antibodies for differentiation of pleural mesothelioma from lung adenocarcinoma

Immunohistochemistry and ELISA quantitation of mucin for diagnosis of malignant pleural effusions

Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3 and cytokeratin 19 fragments) in pleural fluid for differential diagnosis of benign and malignant effusions

Diagnostic implications of telomerase activity in pleural effusions

Window to pleural space

Thoracoscopy: state of the art

Survival time of patients with pleural metastatic carcinoma predicted by glucose and pH studies

Pleural fluid pH in malignant effusions

Low glucose and pH levels in malignant pleural effusions: diagnostic significance and prognostic value in respect to pleurodesis

Pleural fluid pH as a predictor of survival for patients with malignant pleural effusions

Predicting survival in patients with recurrent symptomatic malignant pleural effusions

Evidence for increased permeability in re-expansion pulmonary edema

The relationship between pleural pressures and changes in pulmonary function after therapeutic thoracentesis

Elastance of pleural space. A predictor for the outcome of pleurodesis in patient with malignant pleural effusion

Prediction of results of the talc pleurodesis in malignant pleural effusions

Pleurodesis: state of the art

Sclerotherapy for malignant pleural effusions: a prospective randomized trial of bleomycin vs doxycycline with small bore catheter drainage

Respiratory failure due to insufflated talk

Respiratory failure following talk pleurodesis

Basic fibroblast growth factor mediates pleural fibrosis

Palliative care

Treatment of malignant pleural effusions with doxorubicine hydrochloride-containing poly(l-lactic acid) microspheres

Phase II study of repeated intrapleural chemotherapy using implantable access system for management of malignant pleural effusion

Intrapleural natural beta interferon in the treatment of malignant pleural effusions

Intrapleural recombinant IL-2 in passive immunotherapy for malignant pleural effusion

Intrapleural immunotherapy with escalating doses of IL-2 in metastatic pleural effusions

Intrapleural staphylococcal superantigen induces resolution of malignant pleural effusions and survival benefit in non-small cell lung cancer

Phase III Intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion

Isolated pleural effusion in small cell lung carcinoma

Cancer of the breast

cer Principles and Practice of Oncology. Philadelphia: Lippincott

Malignant pleural and pericardial effusion in invasive breast cancer. Impact of the site of the primary tumor

The value of cells in pleural fluid in the differential diagnosis

Medical thoracoscopy: hormone receptor content in pleural metastases due to breast cancer

FISH cytogenetics and prognosis in breast and non-small cell lung cancers

Control of pleural effusions in patients with breast cancer

Pleural effusion in lymphoma

Pleuroperitoneal shunts in the management of persistent chylothorax

Pleural effusion in multiple myeloma

Aspects of histopathological subtype as a prognostic factor in BS pleural mesotheliomas

Benign and malignant mesothelioma

Simian virus 40 sequence is a negative prognostic factor in patients with malignant pleural mesothelioma

Gene expression profiles predict survival and progression of pleural mesothelioma

Defective core-apoptosis signaling in diffuse malignant pleural mesothelioma: opportunities for effective drug development

Diffuse malignant mesothelioma of the pleural space and its management

A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma

Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma

Chemotherapy options and new advances in malignant pleural mesothelioma

Phase II study of vinorelbine in patients with malignant pleural mesothelioma

Phase III trial of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

Intrapleural administration of interleukin-2 for treatment of patients with malignant pleural mesothelioma: a phase II study

Adenovirusmediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma

Soluble Coxsackie virus adenovirus receptor is a putative inhibitor of adenoviral gene transfer in the tumour milieu

Chapter 49 Management of Malignant Pleural Effusions